

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
13 May 2004 (13.05.2004)

PCT

(10) International Publication Number
WO 2004/039421 A1

(51) International Patent Classification⁷: **A61L 15/14**

Soo-Chang [KR/KR]; 63-103, Jangwe-dong, Sungbuk-gu, 136-827 Seoul (KR). KANG, Sun-Ae [KR/KR]; Mokryun Apartment 308-305, 1052-3, Hogye-dong, Dongan-gu, 431-080 Anyang-city, Kyunggi-do (KR).

(21) International Application Number:
PCT/KR2003/002242

(74) Agent: YOON, Hang-Shik; 9th Floor, BYC Bldg., 648-1, Yeoksam-dong, Gangnam-gu, 135-080 Seoul (KR).

(22) International Filing Date: 23 October 2003 (23.10.2003)

(81) Designated States (*national*): BR, CA, CN, ID, IL, IN, JP, MX, NZ, PH, PL, SG, US.

(25) Filing Language: **Korean**

(84) Designated States (*regional*): European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(26) Publication Language: **English**


Published:

- with international search report
- with amended claims


(71) Applicant (*for all designated States except US*): BIOPOL CO., LTD. [KR/KR]; 226-8, Bacto-ri, Hyangnam-myun, 445-924 Hwasung-city, Kyunggi-do (KR).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and
(75) Inventors/Applicants (*for US only*): PARK, Myung-Hwan [KR/KR]; A-2301, Daelim Acrovil, 467-6, Dogok-dong, Gangnam-gu, 135-270 Seoul (KR). LEE,



WO 2004/039421 A1



(57) Abstract: Disclosed is a polyurethane foam dressing for a wound filler, which includes a hydrophilic polyurethane foam including a plurality of open cells with a diameter of 50 to 400 µm and a plurality of pores with a diameter of 10 to 80 µm, and a method of manufacturing the same. The method includes mixing and agitating 40 to 75 wt% pre-polymer, 15 to 45 wt% foaming agent, 5 to 35 wt% crosslinking agent, and 0.5 to 15 wt% additive containing a surfactant, a moisturizing agent, and a pigment, injecting the resulting mixture into a mold, and foaming the resulting mixture injected into the mold. The foam dressing is advantageous in that it has relatively high moisture vapor transmission rate, absorptivity, and absorption rate. Additionally, after the foam dressing absorbs an exudate, its physical properties are rarely changed, thus it does not leave a portion thereof in the wound.